## RMD: ResMed Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.6% below STRENGTH zone (3.0-6.0%); PEG 1.55 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($235.86)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. ResMed Officer Brett Sandercock Discloses Planned Sale of 1,000 Shares Under Trading Plan**
- Source: TipRanks | 20260105T214516 | Neutral | Relevance: 100%
- ResMed officer Brett Sandercock plans to sell 1,000 common shares on or around January 2, 2026, under a Rule 10b5-1 trading plan. These shares, valued at approximately $241,750, were acquired as restricted stock vesting in November 2022. This planned sale follows a previous disposal of 4,000 ResMed shares by Sandercock, totaling nearly $987,000 in gross proceeds.

**2. ResMed Inc. $RMD Shares Sold by TriaGen Wealth Management LLC**
- Source: MarketBeat | 20260105T130002 | Neutral | Relevance: 100%
- TriaGen Wealth Management LLC reduced its stake in ResMed Inc. (NYSE:RMD) by 50.3% in Q3, selling 7,856 shares and holding 7,758 shares valued at $2.124 million. This comes amidst significant insider selling, with CEO Michael J. Farrell selling shares worth approximately $2 million and insiders selling a total of $5.92 million over the past 90 days. Despite the selling, analysts maintain a "Moderate Buy" rating with a consensus price target of $296.09, and ResMed recently surpassed EPS and revenue expectations.

**3. ResMed Q2 2026 Earnings Preview: EPS Growth Forecast & Analyst Rating | Barchart - News and Statistics**
- Source: IndexBox | 20260105T130848 | Somewhat-Bullish | Relevance: 99%
- ResMed Inc. (RMD) is anticipated to release its fiscal Q2 2026 earnings soon, with analysts forecasting a 10.3% increase in diluted EPS to $2.68. The company has consistently beaten Wall Street's EPS estimates in the previous four quarters. Despite strong earnings performance, RMD shares have lagged behind broader market indices and the healthcare sector over the past 52 weeks, but analysts maintain a "Moderate Buy" consensus with a potential 18.2% upside.

**4. ResMed Inc.: How a Sleep-Tech Powerhouse Is Turning Data, Devices and Chronic Care Into a Platform P**
- Source: AD HOC NEWS | 20260105T060838 | Bullish | Relevance: 98%
- ResMed Inc. has evolved beyond CPAP machines to become a connected respiratory and sleep-therapy ecosystem, integrating data, devices, and chronic care into a platform play. The company leverages cloud-connected devices, patient apps, and enterprise software to offer an end-to-end operating system for sleep and respiratory care, creating a durable competitive edge through scale, an integrated ecosystem, and regulatory expertise. This strategy drives its long-term stock trajectory by expanding the diagnosed sleep-apnea population, capturing market share, and increasing monetization of its connected services.

**5. ResMed (NYSE:RMD) General Counsel Michael Rider Sells 50 Shares**
- Source: MarketBeat | 20260105T205144 | Somewhat-Bullish | Relevance: 98%
- ResMed (NYSE:RMD) General Counsel Michael Rider sold 50 shares of the company's stock on January 2nd at an average price of $241.75, totaling $12,087.50. This transaction, disclosed in an SEC filing, reduced his ownership stake by 0.51% to 9,741 shares. The medical equipment provider recently exceeded earnings expectations, reporting robust financial results including $2.55 EPS and $1.34 billion in revenue.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Stifel | $260 | $270 | -4% |
| 2025-12-16 | Baird | $275 | $300 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Stifel | main | Hold |
| 2025-12-16 | Baird | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 16 ($9.01M) |
| Sells | 14 ($4.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (+1.6%)
- Blackrock Inc.: 8.4% (-1.3%)
- State Street Corpora: 4.5% (-1.0%)
- Bank Of New York Mel: 3.1% (-9.8%)
- Geode Capital Manage: 2.9% (+0.9%)

### Key Risks

1. Insider selling cluster: $5.0M in recent transactions.
2. Elevated short interest (8.3%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Momentum building: MRS_10 improving +2.6% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.55 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 25%, ROA 14%, margin 27%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.36). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $35.8B |
| Beta | 0.88 |
| 52W Range | $199.92 - $293.81 |
| Short Interest | 8.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.55 |
| Forward P/E | 20.4 |
| Current P/E | 22.5 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.0% to 0.6% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.4pp (needs >3.0% for momentum thesis). MRS_5 at 0.7% confirms short-term momentum alignment. Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 46. OFD pattern: +SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.62% (CS: 49) | Neutral |
| RSI_14 | 46.3 | Neutral |
| MACD Histogram | 0.03 | Bullish |
| vs SMA20 | 0.994x | Below |
| vs SMA50 | 0.984x | Below |
| vs SMA200 | 0.964x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $245.44
- **Stop Loss:** $235.86 (3.9% risk)
- **Target:** $255.02 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 90
- **Position Value:** $22,089.60
- **Portfolio %:** 22.09%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-05 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.55 | +2.0% |
| 2025Q2 | $2.48 | $2.55 | +2.8% |
| 2025Q1 | $2.36 | $2.37 | +0.4% |
| 2024Q4 | $2.31 | $2.43 | +5.0% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*